The Medicare specialty threshold is commonly touted as an important factor that could have implications for not only the Medicare channel but also the commercial book of business. We argue that while the specialty threshold can be a key consideration for a minority of therapeutics, using the threshold as a “de facto” decision point is ill-advised for most products.